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Background. Well-established evidence exists of an association between depressive 
symptoms and alterations in the stress and inflammatory response systems; however, the picture 
is far less coherent during the perinatal period. This study combines the assessment of multiple 
stress and inflammatory biomarkers in late pregnancy and after delivery in order to investigate 
cross-sectional and prospective associations with perinatal depressive symptoms. Methods. One-
hundred-ten healthy women were assessed in late pregnancy (mean gestational age=34.76; 
SD=1.12) and 89 were re-evaluated after delivery (mean hours after delivery=52.36; SD=19.70) for 
depressive and anxiety symptoms through the Edinburgh Postnatal Depression Scale and the 
State-Trait Anxiety Inventory. Serum Interleukin-6 (IL-6), C-Reactive Protein (CRP) and diurnal 
salivary cortisol levels were measured on both occasions, while diurnal salivary alpha amylase 
(sAA) levels were assessed in late pregnancy. Results. Using Hierarchical Linear Models, higher 
depressive symptoms were found to be associated with higher IL-6 levels, lower morning cortisol 
levels and a flatter cortisol diurnal slope during pregnancy, while adjusting for potential 
confounders. No significant associations were found after delivery or with change in biomarker 
levels from pre- to post-partum. Furthermore, preliminary evidence of a positive association 
between inflammation and stress markers in women with higher antenatal depressive symptoms 
was found. Limitations: The sample was relatively small and highly selected, thus limiting 
generalizability of the findings. Conclusions. Results emphasize the need for an integrated multi-
systems approach to the understanding of the biological underpinnings of perinatal depression and 








Main text  
1. Introduction 
Perinatal depressive symptoms affect up to 12% of women in high-income countries 
(Woody et al., 2017), with possible negative implications for both maternal and offspring’s health 
and well-being (Gentile, 2017). Research on the biological underpinnings of perinatal depression 
has mostly focused on the role of the Hypothalamic-Pituitary-Adrenal (HPA) axis and its end-
product cortisol, while relatively little is known about the contributions of the Inflammatory 
Response System (IRS) and Sympathetic Nervous System (SNS). The current study adopts a 
short-term longitudinal design and combines the assessment of multiple stress and inflammatory 
biomarkers in late pregnancy and after delivery in order to elucidate possible associations with pre- 
and postnatal depressive symptoms and investigate their change across the perinatal period.   
 
1.1 Stress markers and perinatal depression 
Despite extensive research investigating the associations between perinatal depression 
and cortisol (Orta et al., 2018; Seth et al., 2016), mood-related alterations in the diurnal cortisol 
pattern have been poorly investigated. Alterations in cortisol diurnal rhythm, as indicated by a lower 
waking level (O’Connor et al., 2014), a blunted cortisol awakening response (CAR; Osborne et al., 
2018), a flatter diurnal decline (O’Connor et al., 2014), increased evening (O’Keane et al., 2011; 
Osborne et al., 2018) and averaged daily cortisol (O’Connor et al., 2014; Osborne et al., 2018), in 
clinically depressed pregnant women have been found in some studies, though not all (Shea et al., 
2007; Hellgren et al., 2013). Likewise, a blunted CAR have been reported in depressed women at 
6-8 weeks (Taylor et al., 2009) and 6 months (De Rezende et al., 2016) postpartum, whereas 
Corwin and colleagues (2015) reported higher daily cortisol in depressed women 14 days, but not 
7 days or 6 months after delivery. Conversely, studies on non-clinical samples have failed to detect 
any associations between depressive symptoms and diurnal cortisol measures both prenatally 
(Rash et al., 2015; Heuvel et al., 2018) and postnatally (Cheng & Pickler, 2010, Scheyer & Urizar, 
2016). Large heterogeneity in cortisol measures may play a role in inconsistent findings with 
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studies differing in the selection and computation of composite scores (e.g. CAR, decline, etc.). 
Multilevel analytical models have been recommended for analysing repeated cortisol measures 
(Hruschka et al., 2005; Zijlmans et al., 2015) and might help to detect subtle mood-related 
alterations in cortisol diurnal pattern, yet they are scarcely applied. Furthermore, most studies have 
been cross-sectional and it is unknown whether depressive symptoms are associated with 
changes in diurnal cortisol from pre- to postpartum. 
Initial evidence suggests that salivary α-amylase (sAA), a non-invasive marker of SNS 
activity (Nater & Rohleder, 2009), can be reliably assessed during pregnancy (Nierop et al., 2006) 
and its diurnal patterning (characterized by a rapid decrease after awakening and a gradual 
increase throughout the day) is largely maintained during the prenatal period (Giesbrecht et al., 
2013). However, knowledge about the association between sAA diurnal levels and perinatal 
depression is limited. Braithwaite and colleagues (2015) found higher sAA waking levels in 
pregnant depressed women, while Giesbrecht and colleagues (2013) found no association 
between sAA diurnal trajectory and prenatal depression, although both momentary depressed and 
positive mood were positively associated with sAA. 
 
1.2 Inflammatory markers and perinatal depression 
Mounting evidence indicates a role for inflammation in the pathophysiology of depression 
(Miller and Raison, 2016), with levels of inflammatory markers such as Interleukine-6 (IL-6) and C-
Reactive Protein (CRP) being found consistently increased in depressed patients (e.g. Valkanova 
et al., 2013). However, the generalizability of these findings to the perinatal period is still debated 
(Osborne & Monk, 2013). Either positive (e.g. Cassidy-Bushrow et al., 2012; Christian et al., 2009; 
Liu et al., 2016) or null associations (e.g. Skalkidou et al., 2009; Blackmore et al., 2011; Buglione-
Corbett et al., 2018) between depressive symptoms and IL-6 and/or CRP levels have been 
reported during pregnancy and following birth-to-6 months postpartum. To our knowledge, only 
Osborne and colleagues (2019) have examined whether prenatal depressive symptoms are 
associated with changes in cytokines levels from pre- to post-partum. The authors reported a 
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greater increase in pro-inflammatory cytokines levels, including IL-6, from the second to the third 
trimester of gestation, followed by a greater decrease at 6 weeks postpartum in a small group of 
women (N=12) with higher prenatal depressive symptoms, as compared to non-depressed women 
(N=37). 
 
1.3 Stress-immune interactions 
Besides their individual effects, the stress and inflammatory response systems exhibit 
significant bidirectional interactions (Kuhlman et al., 2017), with a disruption of these circuits being 
hypothesized to increase vulnerability to several disorders (Raison and Miller, 2003), including 
depression (Pariante, 2017). However, studies investigating the concurrent activity of the HPA-axis 
and IRS during the perinatal period are scarce (Corwin et al., 2013; Shelton et al., 2015; Walsh et 
al., 2016) and, to our knowledge, only Corwin and colleagues (2015) examined the link between 
variability in stress-immune interactions and risk for depression. Results showed a positive 
association between inflammation and cortisol in postnatally depressed women, and no 
association in euthymic women. 
 
1.4 Current study 
Although it is increasingly acknowledged that the coordination of the SNS, HPA-axis and 
IRS is essential to health and well-being (Gunnar & Quevedo, 2007; Kuhlman et al., 2017), 
knowledge about the stress-immune interplay during the perinatal period as well as the association 
with perinatal depressive symptoms remains vague. Furthermore, most studies have been cross-
sectional and mood-related changes in biomarker levels over the perinatal period are largely 
unknown. This limited knowledge results in a lack of biomarkers for the diagnosis, prevention and 
treatment of perinatal depression.  
The current study begins to fill these gaps by investigating the cross-sectional and 
prospective associations among naturally occurring variations in depressive symptoms and 
multiple stress (i.e. diurnal cortisol and sAA) and inflammatory (i.e. IL-6 and CRP) markers in late 
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pregnancy and after delivery. We hypothesized that higher depressive symptoms would be 
associated with heightened inflammation and an altered cortisol diurnal pattern. Conversely, no 
formal hypothesis was made regarding the association between depressive symptoms and diurnal 
sAA due to limited available literature. Additionally, supplementary analyses investigated an 
exploratory hypothesis and examined the robustness of the associations found for depression. 
Specifically, we sought to extend findings from Corwin and colleagues (2015) by exploring the 
association among stress and inflammatory markers in women with higher versus lower depressive 
symptoms pre- and post-partum. Furthermore, as perinatal depression and anxiety are strongly 
correlated (Falah-Hassani et al., 2017), we explored whether the observed biological alterations 
were specific to depression or can be replicated for anxiety.  
 
2 Material and methods 
 
2.1  Participants and procedures 
Women at 30-33 gestational weeks were recruited in three Italian hospitals and followed 
longitudinally within the Effects of Depression on Infants (EDI) Study, an on-going study 
investigating the effects of maternal prenatal depression on infants’ development (Nazzari et al., 
2019). Prenatal inclusion criteria were: aged 18-45 years, normotensive, with singleton 
uncomplicated pregnancy, non-smoker, not afflicted by any disease, not taking any chronic 
medications, and with no substance/alcohol abuse problems or psychiatric disorders (except for 
depression and anxiety) as ascertained through the Structured Clinical Interview for DSM-IV-TR 
Axis I Disorders (SCID-I; First, et al., 2002). One-hundred-ten women (mean age= 33.00; SD= 
3.85), were included in the current sample (Table 1). Nineteen caesarean sections and 1 
intrauterine death were excluded from the postnatal phase, and 1 woman withdrew due to her 
newborn’s health problems. Thus, data from 89 women were available at the postnatal phase (see 
Supplemental Figure 1 for a flow diagram of the study design). Women who were excluded from 
the postnatal phase did not differ from participants on any demographic variables, depression or 
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anxiety scores.  
Depressive/anxiety symptoms and biomarkers levels were evaluated at 34-36 gestational 
weeks (mean gestational age=34.76; SD=1.12) and soon after delivery (mean hours after 
delivery=52.36; SD=19.70). On both occasions, women filled out the Edinburgh Postnatal 
Depression Scale, the State-Trait Anxiety Inventory, a health-related information form and provided 
blood samples. Diurnal salivary samples were collected over the two consecutive days preceding 
the pre- and postnatal sessions as described below. 
The Ethics Committee of University College London, of Scientific Institute Eugenio Medea 
and of the hospitals involved approved the study protocol, and all participants gave their written 
informed consent.  
 
2.2  Self-report measures 
Depressive symptoms were evaluated through the Italian version (Benvenuti et al., 1999) of 
the Edinburgh Postnatal Depression Scale (EPDS; Cox et al.,1987), a 10-items questionnaire 
widely used to screen for perinatal depression. The Italian version of the EPDS shows good 
internal consistency (alpha of Cronbach=0.79), high sensitivity and convergent validity with other 
measures of depression, comparably to the original version (Benvenuti et al., 1999). 
Anxiety symptoms experienced in the last few days were assessed through the Italian 
version (Pedrabissi and Santinello, 1989) of the 20-items state-anxiety subscale of the State-Trait 
Anxiety Inventory (STAI-S; Spielberger et al. 1970). The Italian version of the STAI-S shows high 
coefficients of internal consistency (alpha of Cronbach=.91-.92) and good test–retest reliability 
(Spearman correlation=0.49; p<0.01) (Pedrabissi and Santinello, 1989). Furthermore, moderate 
concurrent validity with other measures of anxiety has been reported as well as high ability to 
discriminate between clinical and nonclinical Italian samples (Balsamo et al., 2013). 
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Health-related information was collected through ad-hoc forms in order to examine potential 
health-related confounders of the association between depressive symptoms and biological levels 
(further details in Supplemental Methods).  
 
2.3 Biological measures 
Blood collection and assay. Antecubital venous blood samples were collected in the 
morning (with the exception of 8 postnatal samples) and kept refrigerated at +4° until they reached 
the laboratory where serum was centrifuged, aliquoted, and stored at −80 °C. Serum CRP and IL-6 
concentrations were assayed in duplicate by using Quantikine High Sensitivity ELISA kits (R&D 
Systems Europe, LTD). Ninety-seven women out of 110 (88%) agreed to blood sampling during 
pregnancy and 66 out of 89 (74%) after delivery. As IL-6 and CRP levels assessed in the 
afternoon (N=8) were comparable to those assessed in the morning (respectively, F(1,65)= 0.326, 
p=0.57 and F(1,65)= 1.05, p=0.31), all postnatal samples were included in the analyses.  
Saliva collection and assay. Six unstimulated saliva samples were collected on two 
consecutive days upon awakening, 30 minutes post-waking and before going to bed respectively, 
at home, during pregnancy and, at the hospital, after delivery, according to the same protocol. All 
samples were stored frozen at -80° until assayed for cortisol in duplicate using a competitive high 
sensitivity enzyme immunoassay kit (Salimetrics, UK) and for sAA using a kinetic enzyme assay kit 
(Salimetrics, UK).  Due to budget restrictions, sAA was examined only in pregnancy. All women 
provided completed saliva samples during pregnancy, 12 women had incomplete postnatal salivary 
data and 9 women had no postnatal salivary data. Women with complete, partial or missing 
postnatal data did not differ on any sociodemographic, health-related variables, depression or 
anxiety scores. One prenatal 30-min post-waking sample and 4 postnatal 30-min post-waking 
samples, collected more than one hour from awakening, were excluded from analyses (e.g. 
O’Connor et al. 2014). Further details are reported in Supplemental Methods. 
 
2.4  Statistical analyses 
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Variables were first examined for outliers and skewness. The distributions of the biological 
markers were positively skewed even after removing samples greater than 3 SD from the mean 
(n=7 samples for prenatal cortisol, n=8 for postnatal cortisol, n=4 for sAA, n=3 for prenatal IL-6), 
thus measures were natural log transformed prior to analysis to approximate normal distributions.  
Given the low-risk nature of the current sample and the focus of the study on naturally 
occurring variations in maternal symptoms across the whole normative range, the total score of the 
EPDS/STAI was employed as a continuous variable in the main analyses.  
Hierarchical Linear Models (HLMs) were estimated to investigate: 1) the cross-sectional 
association between depressive symptoms and biological levels in pregnancy and after delivery; 2) 
the prospective association between prenatal depressive symptoms and the change in markers 
levels from pre- to post-partum. HLMs allow to partition different sources of variance and provide 
robust estimates despite missing values by maximizing all valid data point (Hruschka et al., 2005). 
Final sample size for the main analyses is provided in Supplemental Figure 1. Full model 
specification is provided in Supplemental Methods. Preliminary models examined demographic, 
health-related and situational factors, known to affect stress and immune physiology. Variables 
significantly associated with biological markers in these analyses were included as controls in 
subsequent analyses. The fixed effects of maternal depressive symptoms on the intercept and time 
slopes were tested sequentially. Model fit was tested with likelihood deviance difference test for 
nested models. Model parameters for ln-transformed cortisol values are presented in tables, while 
results in figures are presented using anti-logged values. A sensitivity power analyses estimated 
that with the current sample size and 80% power at a 0.05 level of significance, we were able to 
detect effects ranging from f2=.11 to f2=.16, while we would have missed any effect smaller than 
this. 
Supplementary analyses preliminarily explore stress-immune interactions. Daily average 
cortisol and sAA were computed for each day as the area under the curve according to the 
trapezoid method with respect to the ground (AUCg, Pruessner et al., 2003) and, as they were 
highly correlated (r(104)=.57, p<.001 for cortisol and r(106)=.75, p<.001 for sAA), the mean of the 
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2 days was used. After Corwin and colleagues (2015), graphical analyses were used to explore 
different patterns of correlations between sAA or cortisol AUCg and inflammatory markers between 
women scoring above versus under the EPDS median during pregnancy and after delivery. At time 
points where significant differences were identified, the relationship trends were further 
investigated through multiple linear regressions. In these models, levels of inflammation were the 
outcomes variables and the difference in the relationship patterns between stress and 
inflammatory markers was evaluated by testing the significance of the interaction term between 
EPDS and cortisol/sAA AUCg on levels of inflammation.  
Lastly, given the considerable overlap between depression and anxiety (r=.65 prenatally 
and r=.46 postnatally, p<.001), comparable HLMs examined anxiety, rather than depression, as 
individual-level predictor.  
Statistical analyses were performed using SPSS 24 and MLWiN 3.02.  
 
3. Results  
Descriptive raw values for all study variables are presented in Table 2.  
 
3.1 Diurnal cortisol  
3.1.1 Diurnal variation in prenatal cortisol  
The baseline model for prenatal cortisol (Table 3) indicated significant between-person 
variation in mean waking cortisol levels (p<.001) and showed the typical cortisol diurnal pattern 
found in non-pregnant samples (both morning and afternoon slopes ps<.001). Fetal sex was 
significantly associated with cortisol mean waking level (p=.005), with 2.9% lower values in women 
carrying a female fetus as compared to male, and was thus included as a control in all subsequent 
models. No other significant associations between cortisol levels and demographic, pregnancy-
related or situational variables were found (all ps>.05). Higher prenatal depressive symptoms, as 
assessed through the EPDS, were associated with lower cortisol levels at waking and 30 minutes 
after waking (respectively, 2.6% and 3% lower with every 1-point EPDS increase, ps=.002), and 
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with a flatter afternoon cortisol decline (2.2% smaller slope with every 1-point increase on the 
EPDS, p=.019), after adjusting for covariates. While the EPDS score was modeled as a continuous 
variable, for illustrative purposes, prenatal maternal cortisol trajectories are displayed in Figure 1 
for women with higher (+1SD) and lower (-1SD) EPDS score. Inclusion of depressive symptoms 
resulted in a significant improvement of model fit over the baseline model (deviance difference 
(3)=12.44, p=.01).  
 
3.1.2 Diurnal variation in postnatal cortisol  
 The expected cortisol diurnal pattern was found soon after delivery (both morning and 
afternoon slopes ps<.001), with significant between-day (level-2, σ2u0=0.017, p<.001) and 
between-person (level-3, σ2v0=0.004, p<.001) variation in mean waking cortisol levels. There was a 
marginally significant effect of time from delivery (estimate=-0.002, SE=0.001, p=.07) on cortisol 
waking levels. Thus, time from delivery was included as a covariate in subsequent models. All 
other demographic and health-related variables were not significantly associated with cortisol 
values (all ps>.05). No significant effects of postnatal EPDS scores on mean cortisol waking levels 
(p=.15), on morning (p=.21) and afternoon (p=.18) slopes were found.  
 
3.1.3 Diurnal variation in cortisol from pregnancy to delivery 
The unconditional means model for the change in diurnal cortisol from pregnancy to 
delivery revealed significant variability between occasions (i.e. pregnancy versus delivery; level-3 
p<.001). As expected, mean cortisol waking values were 3.25% higher at delivery as compared to 
prenatal levels (p<.001), while no effect of sampling occasion (i.e. pregnancy or delivery) on 
cortisol diurnal slopes was found (ps>.05). Both foetal sex and time from delivery were retained in 
the model as they were previously associated with cortisol levels. Prenatal depressive symptoms 
were associated with lower waking cortisol values prenatally (estimate=-0.03, SE=0.01; p=.01), but 
not postnatally (estimate=0.01, SE=0.01; p=.31). Additionally, prenatal depressive symptoms were 
related to a greater increase in cortisol waking levels from pregnancy to delivery (estimate=0.046, 
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SE=0.017; p=.006). However, the inclusion of a three-way interaction between prenatal depressive 
symptoms, time of sampling and occasions did not significantly improve the model fit over the 
baseline model (deviance difference (6)=11.3, p=0.08).  
 
3.2 Diurnal sAA 
The expected sAA diurnal trajectory was observed (both morning and afternoon slopes 
ps<.001), with significant variability in sAA waking values between persons and days (ps<.001). 
There was a significant effect of day of collection on mean sAA waking values (p=.002), but not on 
diurnal slopes, with higher levels on day 2 as compared to day 1. Thus, day of collection was 
retained as a covariate. Demographic, pregnancy-related and situational variables were not 
significantly associated with diurnal sAA levels (all ps>.05). 
As shown in Table 3, there was no effect of depressive symptoms on mean sAA waking 
levels (p=.22) or diurnal pattern (note that there was a non-significant tendency for depressive 
symptoms to be related to a flatter morning sAA decline (p=.07), while no effects on sAA afternoon 
slope, p=.35). Inclusion of depressive symptoms did not significantly improve model fit over the 
baseline model (deviance difference (3)=3.78, p=.29). 
 
3.3 Inflammatory markers 
As expected, both CRP and IL-6 levels were significantly higher after delivery as compared 
to late pregnancy (both ps<.001, Table 4), with significant between-person variations in  prenatal 
markers levels as well as change from pregnancy to delivery (all ps<.001). There was a significant 
effect of pre-pregnancy Body Mass Index (BMI), as assessed through the health-related form, and 
age on CRP prenatal levels and on the time slope. Specifically, we observe 5.5% lower CRP levels 
per year older (p=.003) and 8.9% higher CRP with each point on the BMI (p<.001). Additionally, a 
higher BMI and a younger age were related to a flatter CRP increase from pregnancy to delivery 
(deviance difference (4)=30.3, p<.001). Thus, both maternal age and BMI were included in all 
subsequent models. Furthermore, BMI was significantly associated with prenatal IL-6 levels 
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(p=.016), with 4.4% higher IL-6 concentrations with each BMI point, and was included as a 
covariate in subsequent analyses. 
There was a significant effect of prenatal depressive symptoms on IL-6 levels during 
pregnancy with around 7.7% higher IL-6 concentrations with every 1-point EPDS increase (p=.04), 
although no effect on IL-6 pre- to post-partum slope (p=.72). The inclusion of depressive symptoms 
significantly improved the model fit over the baseline model (deviance difference (1)= 4.02, 
p=0.04). In contrast, prenatal depressive symptoms were not significantly related to mean prenatal 
CRP levels or slope (all ps>.05). Similarly, no effects of postnatal depressive symptoms on mean 
CRP or IL-6 postnatal levels were found (all ps>.05).  
 
3.4 Supplementary Results  
3.4.1 Correlations between systems  
Table 5 shows bivariate correlations between EPDS scores and biological levels.  
As shown in Supplemental Figure 2, the relationship patterns for IL-6 and both cortisol and 
sAA during pregnancy were quite different among women who scored above or below the EPDS 
median. Specifically, in women scoring above the EPDS median (N=66), prenatal cortisol AUCg 
and sAA AUCg increased with increasing levels of IL-6 (respectively, p=.03 and p=.002), while this 
was not true in women scoring below the median (both ps>.05). No differences in relationship 
trends were apparent after delivery.  
To further explore these relationship patterns during pregnancy, separate regression 
models were fitted. There was no main effect of cortisol or sAA AUCg on mean IL-6 or CRP levels 
during pregnancy (all ps>.05). However, there was a significant interaction between prenatal 
depressive symptoms and sAA (p<.01) in relation to IL-6 levels during pregnancy, while the 
interaction between prenatal depressive symptoms and cortisol was not significant (p=.06). 
Specifically, higher sAA levels were associated with higher IL-6 levels only in women with higher 
EPDS scores (+1SD; p<.05), while the association was non-significant in women with lower EPDS 
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scores (p>.05). The sAA model yielded a significant improvement in model fit as compared to the 
baseline model (deviance difference (2)=12.97, p<.01).  
 
3.4.2. Anxiety symptoms 
There were no significant effects of anxiety symptoms, as assessed through the STAI-S, on 
cortisol, IL-6 and CRP levels both prenatally and postnatally (all ps>.05). However, there was a 
significant main effect of prenatal anxiety on mean waking sAA levels (estimate=-0.663, SE=0.312; 
p=.033) and on sAA morning slope (estimate=0.594, SE=0.209; p=.004). Specifically, higher STAI 
scores were related to lower waking sAA concentrations and a flatter decline from waking to 30 
minutes after. This model significantly improved model fit over the baseline model (deviance 




The present study is among the first to investigate the concurrent and short-term 
functioning of the HPA-axis, SNS and IRS from pre- to post-partum in association with perinatal 
depressive symptoms.    
In line with our predictions, higher depressive symptoms in late gestation, as assessed 
through the EPDS, were associated with heightened IL-6 levels and an altered cortisol diurnal 
pattern, as indexed by lower morning cortisol levels (i.e. at waking and 30 minutes after) and a 
flatter diurnal decline. In contrast with our initial hypothesis, however, no significant associations 
were found in the early postpartum. Furthermore, exploratory analyses indicate that anxiety, but 
not depressive, symptoms were associated with an altered sAA diurnal profile and that the 
interplay between inflammatory and stress markers during pregnancy might be different in women 
with higher depressive symptoms.  
Evidence exists of an altered diurnal cortisol pattern in clinically depressed (O’Connor et al., 
2014) or minority high-stressed (Suglia et al., 2010) pregnant women; likewise, an association 
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between depressive symptoms and elevations in circulating IL-6 levels has been reported in 
samples of low-income high-psychosocial risk (Cassidy-Bushrow et al., 2012; Christian et al., 
2009) and clinically depressed (Haeri et al., 2013; Osborne et al., 2018) pregnant women. The 
current findings support and extend these studies by showing that depressive symptoms, even 
without meeting the full criteria for a clinical diagnosis, are associated with an altered stress-related 
physiology in a low-risk sample of pregnant women. These results converge with evidence of 
depression as a dimensional “trait” in the general population, rather than a discrete entity, with a 
continuous measure of risk underlying the clinical phenotype (e.g. Wray et al., 2018). It is important 
to note that the overall diurnal cortisol output during pregnancy, as indexed by the AUCg, was not 
significantly associated with depressive symptoms. One methodological implication is that a 
detailed characterization of the diurnal pattern, both through multiple sampling and multilevel 
analytical techniques, is needed in order to detect reliable associations between depressive 
symptoms and subtle disturbances in diurnal cortisol profile that would be undetectable otherwise. 
Indeed, as cortisol levels increase (e.g. Allolio et al., 1990) and maternal HPA-axis becomes 
gradually less responsive to stress as pregnancy advances (Kammerer et al., 2002), the 
association between maternal distress and cortisol might become more difficult to detect. 
Furthermore, the current findings align with increasing evidence indicating that diurnal cortisol 
measures, rather than absolute levels, better allow to capture the HPA-axis individual variability 
and are more strongly associated with psychosocial stress measures (Pruessner et al., 2003, 
Harville et al., 2009). Additionally, evidence of an association between prenatal depressive 
symptoms and a flatter diurnal cortisol decline is in line with recent meta-analytical findings in the 
general population (Adam et al., 2017) and possibly indicates that the diurnal cortisol slopes 
represent a biological marker of emotional health that deserves further investigation.  
Findings of an association between increased IL-6 levels and depressive symptoms during 
pregnancy converge with meta-analytical evidence in non-pregnant samples (Dowlati et al., 2010; 
Valkanova et al., 2013). This result in a sample of healthy pregnant women might suggest that the 
experience of depressive symptoms per se is associated with a higher pro-inflammatory state 
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during pregnancy. As initial evidence in humans indicates that higher than typical elevations in pro-
inflammatory cytokines during pregnancy are associated with a range of altered 
neurodevelopmental outcomes in the offspring (reviewed in Nazzari & Frigerio, 2020), including 
birth outcomes (e.g. Ernst et al., 2011; Nazzari et al., 2019), cognitive outcomes (e.g. Nazzari et 
al., in press; Rasmussen et al., 2019) and structural and functional brain alterations (e.g. Graham 
et al., 2017; Rudolph et al., 2018), future studies should investigate possible inflammatory 
pathways from maternal depression to adverse offspring’s development. 
It is noteworthy that the current study was sufficiently powered to detect medium to large 
effect size, thus the fact that we did find significant associations between antenatal depressive 
symptoms and biological alterations is possibly suggestive of a relatively large size of the effect, 
although further replication is needed. The pathways underlying the observed associations are still 
to be understood. Depression and both inflammation and dysregulation of the HPA-axis might 
share a somewhat common genetic background (Spijker & van Rossum, 2009; Barnes et al., 2017; 
Wray et al., 2018). Additionally, as both the stress and immune response systems are extremely 
responsive to environmental adversities, early adverse experiences might affect their functioning 
and confer vulnerability for later mental health problems (Pariante et al., 2017).  
However, the correlational nature of this study and the short-term longitudinal design do not 
allow to establish whether the observed associations reflect causal processes.  
Importantly, the inflammatory and stress response systems function in a complex 
interdependent manner over time. Thus, abnormal inflammation or dysregulation of the HPA-axis 
has the potential to disrupt this circuit, carrying potentially adverse consequences for mental and 
physical health (Khulman et al., 2017). While a disruption of the stress-immune circuits is 
hypothesized to play a role in the pathophysiology of depression in the general population (Pace et 
al., 2007; Irwin & Cole, 2013), the interplay among stress hormones and inflammation across the 
perinatal period is largely unexplored. Our exploratory analyses provide evidence of a positive 
association between IL-6 levels and both higher diurnal sAA and, to a lesser extent, cortisol 
concentrations in women with higher depressive symptoms during pregnancy. It has been 
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hypothesized that increased levels of stress hormones in late gestation might inhibit pro-
inflammatory cytokines production and potentiate production of anti-inflammatory cytokines 
(Elenkov & Chrousos, 2002). Initial evidence indicates an impairment of the negative feedback 
relationship between cortisol and pro-inflammatory cytokines in high-risk pregnant samples 
(Corwin et al., 2013; Walsh et al., 2016). Current results show a positive association between 
stress and inflammatory markers in pregnant women with higher depressive symptoms, possibly 
suggesting that the stress-immune interplay offers a promising avenue for future endeavor into the 
biological underpinnings of perinatal depression. Nevertheless, it is important to emphasize that 
the current findings are small-scale and exploratory and need replication in larger and clinical 
samples.  
It is noteworthy that despite the strong association between prenatal depression and 
anxiety, cortisol diurnal alterations and heightened inflammation were more robustly observed for 
depressive symptomatology, whereas weak and non-significant associations were found for 
anxiety symptoms. Conversely, prenatal anxiety symptoms were significantly associated with an 
altered sAA diurnal pattern, as indicated by lower sAA waking levels and a flatter morning decline, 
in line with few reports of an alteration of sympathetic function in prenatally anxious women (e.g. 
Field et al., 2006; Giesbrecht et al., 2013). Future studies should directly compare these two 
conditions in larger samples and elucidate whether, despite being comorbid, depression and 
anxiety during the perinatal period differ in some respects in their underlying biology. 
Some non-significant findings are worth mentioning. First, we did not report any significant 
association between depressive symptoms and either inflammation or cortisol after delivery. 
Similarly, there was no substantial evidence of an association between prenatal depressive 
symptoms and change in cortisol and inflammatory markers concentrations from pre- to post-
partum. A lack of association among postnatal depression and levels of inflammation or cortisol in 
the immediate postpartum period is in line with previous evidence (e.g. Skalkidou et al., 2009; 
Corwin et al., 2015) and supports the hypothesis that, despite the strong continuity between pre- 
and postnatal depression, they might reflect somewhat different endocrine and inflammatory states 
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(Kammerer et al., 2006). Alternatively, methodological issues might account for these null findings. 
First, the lack of associations in the postnatal period might be an issue of power, as the sample 
size at the postnatal phase was slightly decreased. Alternatively, the association between 
depressive symptoms and biomarkers levels during the first week after childbirth might be masked 
by the strong hormonal and inflammatory response to delivery. It is possible that, as the biological 
response to delivery normalizes, significant associations might emerge. Indeed, significant 
associations between diurnal cortisol levels and depression 2 weeks, but not 1 week (Corwin et al., 
2015), 7 weeks (Taylor et al., 2009) and 6 months postpartum (De Rezende et al., 2016) have 
been observed. Similarly, Osborne and colleagues (2019) reported a greater decrease in IL-6 
levels from late pregnancy to 6 weeks postpartum among women with higher prenatal depressive 
symptoms. Furthermore, a follow-up evaluation of depressive symptoms could reveal significant 
differences in levels of cortisol and inflammation after delivery in women who later developed 
postpartum depression. Consistently with this, Liu and colleagues (2016) reported higher CRP and 
IL-6 levels after delivery in women with postpartum depression 6 months later.   
 Lastly, in contrast with previous studies (e.g. Scrandis et al., 2008; Azar & Mercer, 2013), 
CRP levels were not related to depressive symptomatology. Although CRP is considered a non-
specific marker of systemic inflammation, evaluating “basal” CRP levels is challenging and it is not 
possible to rule out a wide range of factors influencing circulating levels (Du Clos and Mold, 2004), 
including acute infections (e.g. Rasmussen et al., 2018). Therefore, the lack of association 
between CRP and depression may be due to methodological issues. Alternatively, as null 
associations have been already reported (e.g. Cassidy-Bushrow et al. 2012; Catov et al., 2014), it 
remains plausible that IL-6, rather than CRP, is a more adequate biomarker for perinatal 
depression, driving the association between inflammation and depressive symptoms.  
 
5 Limitations 
Some limitations of the present study are noteworthy. First, data are based on a relatively 
small community sample of middle-high SES healthy women and, as expected, self-reported 
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depressive symptoms were relatively low, thus limiting generalizability to high psychosocial risk or 
clinical psychiatric populations. Second, data were collected only in late pregnancy and early 
puerperium. We cannot rule out that effects earlier in pregnancy or later postpartum may be 
different. Third, compliance with the saliva collection protocol was not objectively measured. 
Fourth, although several potential confounders were statistically controlled, we cannot rule out 
unmeasured confounds or third variables that might explain the observed associations, including 
genetic variants. Lastly, we did not evaluate sAA levels postpartum. While conclusions that can be 
drawn from the current study are to be regarded as preliminary and require replication in different 
and larger cohorts, the current study leads the way to future research adopting a multi-systems 
approach to the investigation of perinatal depression.  
 
6 Conclusions 
The current study adds to the growing literature suggesting a dysregulation of the HPA-axis 
and IRS in prenatal depression and emphasizes the need for an integrated multi-systems 
approach to the understanding of the biological underpinnings of perinatal depression. Confirming 
our findings in larger samples may help to identify early biomarkers and treatment targets for 
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Table 1 – Description of the study population (N=110) 
* Percentages for Family SES do not add to100% due to missing values.  
 
 
Variables N (%) or Mean (SD) 
Age M=33.01, SD=3.85  
Education  
< 10 years 


































Pre-pregnancy Body Mass Index (BMI) 22.00 (0.4) 
Actual BMI 25.00 (0.4) 
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Table 2 - Descriptive statistics for study variables during pregnancy and after delivery 
 Pregnancy Delivery 
 Mean SD Range Mean SD Range 
Cortisol (µg/dl)       
Waking 0.38 0.13 0.13-0.83 0.43 0.18 0.02-0.97 
Waking +30’  0.50 0.15 0.10-0.91 0.57 0.25 0.03-1.60 
Bedtime 0.18 0.06 0.01-0.41 0.20 0.09 0.03-0.45 
sAA (U/ml)       
Waking 68.68 63.75 3.00-463.84 -- -- -- 
Waking +30’  47.60 37.97 2.80-190.10 -- -- -- 
Bedtime 97.17 79.58 3.28-562.71 -- -- -- 
CRP (ng/ml) 3786.74 2772.98 480.04-11244.10 11660.28 3541.09 6981.27-18156.9 
IL-6 (pg/ml) 1.67 1.02 0.48-6.47 7.02 2.86 1.68-12.62 
EPDS 5.37 4.41 0-19 5.53 4.77 0-28 












Table 3 – Preliminary (Model 1) and full (Model 2) prediction models for prenatal diurnal cortisol and sAA 
Prenatal cortisol Model 1 Model 2 Prenatal sAA Model 1 Model 2 
 Estimate SE p Estimate SE p  Estimate SE p Estimate SE p 
Fixed effects       Fixed effects       
Intercept 0.329 0.008 <.001 0.327 0.008 <.001 Intercept 3.731 0.079 <.001 3.731 0.079 <.001 
Morning 0.086 0.010 <.001 0.092 0.024 <.001 Morning -0.242 0.052 <.001 -0.241 0.051 <.001 
Afternoon -0.152 0.007 <.001 -0.188 0.017 <.001 Afternoon 0.460 0.066 <.001 0.461 0.066 <.001 
Fetal sex -0.029 0.010 0.005 -0.026 0.010 0.009 Sampling day 0.140 0.042 0.002 0.140 0.042 0.002 
EPDS    -0.026 0.008 0.002 EPDS    -0.126 0.104 0.223 
EPDS X Morning    -0.004 0.014 0.778 EPDS X Morning    0.128 0.069 0.065 
EPDS X Afternoon    0.022 0.009 0.019 EPDS X Afternoon    0.083 0.090 0.354 
Random effects       Random effects       
Level 3 (individual)       Level 3 (individual)       
Intercept variance 0.002 0.001 <.001 0.002 0.001 <.001 Intercept variance 0.498 0.077 <.001 0.497 0.077 <.001 
Morning slope 
variance 
0.005 0.001 <.001 0.005 0.001 <.001 Afternoon slope 
variance 
0.193 0.058 <.001 0.194 0.057 <.001 
Intercept/morning 
slope covariance 
0.000 0.001 0.668 0.000 0.001 0.871 Intercept/afternoon 
slope covariance 
-0.127 0.050 0.011 -0.127 0.050 0.011 
Level 2 (day)       Level 2 (day)       
Intercept variance 0.005 0.000 <.001 0.005 0.000 <.001 Intercept variance 0.287 0.020 <.001 0.285 0.019 <.001 
Level 1 (times)       Level 1 (times)       
Intercept variance 0.000 0.000 0.998 0.000 0.000 0.998 Intercept variance 0.000 0.000 0.999 0.000 0.000 0.999 
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Table 4 – Full prediction models for inflammatory markers change from pregnancy to delivery 
 IL-6 CRP 
 Estimate SE p Estimate  SE P 
Fixed effects       
Intercept 0.935 0.029 <.001 7.968 0.070 <.001 
Time 1.089 0.050 <.001 1.355 0.074 <.001 
Age    -0.054 0.018 0.003 
BMI 1.699 0.709 0.016 0.086 0.018 <.001 
EPDS 0.077 0.039 0.045 0.074 0.094 0.436 
Age x Time    0.039 0.019 0.046 
BMI x Time    -0.081 0.019 <.001 
EPDS X Time -0.023 0.064 0.724 -0.155 0.098 0.114 
Random effects       
Level 2 (individual)       
Intercept variance 0.081 0.012 <.001 0.473 0.068 <.001 
Time variance 0.166 0.030 .001 0.485 0.075 <.001 
Intercept/time    
covariance 
-0.051 0.015 <.001 -0.445 0.068 <.001 
Level 1 (times)       












Table 5 - Bivariate correlations for primary study variables 












 1 2 3 4 5 6 7 8 
1. Prenatal EPDS         
2. Prenatal Cortisol 
AUCg -.15        
3. Prenatal sAA 
AUCg .05 .25**       
4. Prenatal IL-6 .19* .10 .17      
5. Prenatal CRP .11 .08 -.01 .31**     
6. Postnatal EPDS .44** -.13 .07 .14 .19    
7. Postnatal Cortisol 
AUCg -.13 .09 -.16 -.09 -.03 -.20   
8. Postnatal IL-6 .12 .01 .06 .27* .08 .005 .09  




Figure 1- Graphical representation of the effect of maternal depressive symptoms on diurnal 
cortisol levels during pregnancy. Cortisol levels are plotted for women with higher (+1 SD) and 
lower (-1SD) depressive symptoms during pregnancy, after adjusting for covariates. 
 
 
 
 
